Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing a real-world database in Japan. We analyzed 179 patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimazu, Yutaka, Kanda, Junya, Kosugi, Satoru, Ito, Tomoki, Kaneko, Hitomi, Imada, Kazunori, Shimura, Yuji, Fuchida, Shin-ichi, Fukushima, Kentaro, Tanaka, Hirokazu, Yoshihara, Satoshi, Ohta, Kensuke, Uoshima, Nobuhiko, Yagi, Hideo, Shibayama, Hirohiko, Yamamura, Ryosuke, Tanaka, Yasuhiro, Uchiyama, Hitoji, Onda, Yoshiyuki, Adachi, Yoko, Hanamoto, Hitoshi, Takahashi, Ryoichi, Matsuda, Mitsuhiro, Miyoshi, Takashi, Takakuwa, Teruhito, Hino, Masayuki, Hosen, Naoki, Nomura, Shosaku, Shimazaki, Chihiro, Matsumura, Itaru, Takaori-Kondo, Akifumi, Kuroda, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060246/
https://www.ncbi.nlm.nih.gov/pubmed/36991096
http://dx.doi.org/10.1038/s41598-023-32426-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060246/
https://www.ncbi.nlm.nih.gov/pubmed/36991096
http://dx.doi.org/10.1038/s41598-023-32426-6

Ejemplares similares